Diverse effects of 5-HT2C receptor blocking agents on c-Fos expression in the rat basal ganglia

European Journal of Pharmacology

Volumn 689, Issue 1-3, 2012, Pages 8-16

  Kadiri, Nabila ^a   Lagière, Mélanie ^a   Le Moine, Catherine ^a   Millan, Mark J ^b   De Deurwaerdère, Philippe ^a   Navailles, Sylvia ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

5 HT2C pharmacology; 5 HT2C receptor; Basal ganglia; c Fos expression; Constitutive activity; Endogenous 5 HT tone

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXYL] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; N PYRIDIN 3 YL 1,2 DIHYDRO 3H BENZO[E]INDOLE 3 CARBOXAMIDE; PROTEIN C FOS; S 32006; SEROTONIN 2C ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG TARGETING; ENTOPEDUNCULAR NUCLEUS; GLOBUS PALLIDUS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; THALAMUS VENTRAL NUCLEUS;

ANIMALS; BASAL GANGLIA; GENE EXPRESSION REGULATION; MALE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84864290201     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.05.022     Document Type: Article

References (50)

1. K.D. Alex, G.J. Yavanian, H.G. McFarlane, C.P. Pluto, and E.A. Pehek Modulation of dopamine release by striatal 5-HT2C receptors Synapse 55 2005 242 251 (Pubitemid 40256305)
2. G.E. Alexander, and M.D. Crutcher Functional architecture of basal ganglia circuits: neural substrates of parallel processing Trends Neurosci. 13 1990 266 271 (Pubitemid 20193456)
3. J.E. Belforte, and J.H. Pazo Turning behaviour induced by stimulation of the 5-HT receptors in the subthalamic nucleus Eur. J. Neurosci. 19 2004 346 355 (Pubitemid 38177873)
4. K.A. Berg, S. Navailles, T.A. Sanchez, Y.M. Silva, M.D. Wood, U. Spampinato, and W.P. Clarke Differential effects of 5-methyl-1-[[2-[(2-methyl-3- pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-hydroxytryptamine(2C) receptor-mediated responses J. Pharmacol. Exp. Ther. 319 2006 260 268 (Pubitemid 44455131)
5. A. Beyeler, N. Kadiri, S. Navailles, M. Ben Boujema, F. Gonon, C. Le Moine, C. Gross, and P. De Deurwaerdère Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia Neuroscience 169 2010 158 170
6. B.B. Carlson, A. Wisniecki, and J.D. Salamone Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor Psychopharmacology (Berl) 165 2003 229 237 (Pubitemid 36197597)
7. B. Chanrion, C. Mannoury la Cour, S. Gavarini, M. Seimandi, L. Vincent, J.F. Pujol, J. Bockaert, P. Marin, and M.J. Millan Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction Mol. Pharmacol. 73 2008 748 757
8. 2C receptor protein in the rat CNS Neuropharmacology 39 2000 123 132
9. P. De Deurwaerdère, and M.F. Chesselet Nigrostriatal lesions alter orofacial dyskinesia and c-fos expression induced by the serotonin agonist 1-(m-cholophenyl)piperazine in adult rats J. Neurosci. 20 2000 5170 5178 (Pubitemid 30421720)
10. P. De Deurwaerdère, C. Le Moine, and M.F. Chesselet Selective blockade of serotonin2C receptor enhances Fos expression specifically in the striatum and the subthalamic nucleus within the basal ganglia Neurosci. Lett. 469 2010 251 255
11. P. De Deurwaerdère, L. Mignon, and M.F. Chesselet Physiological and pathophysiological aspects of 5-HT2C receptors in basal ganglia G. Di Giovanni, V. Di Matteo, E. Esposito, The Pathophysiology of Central 5-HT2C Receptors 2011 Humana Press, Springer In: Neve, K. (Ed.), The Receptors series
12. 2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens J. Neurosci. 24 2004 3235 3241 (Pubitemid 38451889)
13. A. Dekeyne, C. Mannoury la Cour, A. Gobert, M. Brocco, F. Lejeune, F. Serres, T. Sharp, A. Daszuta, A. Soumier, M. Papp, J.M. Rivet, G. Flik, T.I. Cremers, O. Muiller, G. Lavielle, and M.J. Millan S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models Psychopharmacology (Berl) 199 2008 549 568
14. A. Dekeyne, and M.J. Millan Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization Psychopharmacology (Berl) 203 2009 329 341
15. G. Di Giovanni, V. Di Matteo, M. Pierucci, A. Benigno, and E. Esposito Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies? Curr. Med. Chem. 13 2006 3069 3081 (Pubitemid 44509709)
16. V. Di Matteo, M. Pierucci, E. Esposito, G. Crescimno, A. Benigno, and G. Di Giovanni Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinsons disease and other disorders Prog. Brain Res. 172 2008 423 463
17. K. Eberle-Wang, Z. Mikeladze, K. Uryu, and M.F. Chesselet Pattern of expression of the Serotonin2C receptor messenger RNA in the basal ganglia of adults rats. J. Comp. Neurol. 384 1997 233 247 (Pubitemid 27282041)
18. P.J. Fletcher, M. Tampakeras, J. Sinyard, A. Slassi, M. Isaac, and G.A. Higgins Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice Neuropharmacology 57 2009 259 267
19. 2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinsons disease Exp. Neurol. 151 1998 35 49 (Pubitemid 28223854)
20. A. Gunes, M-L. Dahl, E. Spina, and M. Scordo Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients Eur. J. Clin. Pharmacol. 64 2008 477 482
21. P. Hughes, and M. Dragunow Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47 1995 133 178
22. R.W. Invernizzi, M. Pierucci, E. Calcagno, G. Di Giovanni, V. Di Matteo, A. Benigno, and E. Esposito Selective activation of 5-HT2C receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study Neuroscience 144 2007 1523 1535 (Pubitemid 46138024)
23. A. Javed, L.D. Van de Kar, and T.S. Gray The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain Brain Res. 791 1998 67 74 (Pubitemid 28238311)
24. G.A. Kennett, M.D. Wood, F. Bright, J. Cilia, D.C. Piper, T. Gager, D. Thomas, G.S. Baxter, I.T. Forbes, P. Ham, and T.P. Blackburn In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with an anxiolytic-like properties. Br. J. Pharmacol. 117 1996 427 434
25. R.M. Kostrzewa, N.Y. Huang, J.P. Kostrzewa, P. Nowak, and R. Brus Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment Neurotox. Res. 11 2007 41 50
26. R.J. Lefkowitz, S. Cotecchia, P. Samama, and T. Costa Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins Trends Pharmacol. Sci. 14 1993 303 307 (Pubitemid 23242583)
27. J.E. Leysen 5-HT2 receptors Curr. Drug Targets CNS Neurol. Disord. 3 2004 11 26
28. 2 receptor subfamily Life Sci. 59 1996 1081 1095 (Pubitemid 26284411)
29. A.C. McCreary, and K.A. Cunningham Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine Neuropsychopharmacology 20 1999 556 564 (Pubitemid 29189260)
30. 13 and pertussis toxin-sensitive Gβγ subunits Mol. Pharmacol. 62 2002 1339 1343 (Pubitemid 35403828)
31. A. Mehta, K. Eberle-Wang, and M.F. Chesselet Increased m-CPP induced dyskinesia after lesions of serotonergic neurons Pharmacol. Biochem. Behav. 68 2001 347 353 (Pubitemid 32231197)
32. M.J. Millan Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies Thérapie 60 2005 441 460
33. M.J. Millan, P. Marin, M. Kamal, R. Jockers, B. Chanrion, M. Labasque, J. Bockaert, and C. Mannoury la Cour The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors Int. J. Neuropsychopharmacol. 15 2010 1 16
34. H. Moukhles, O. Bosler, J.P. Bolam, A. Vallée, D. Umbriaco, M. Geffard, and G. Doucet Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigra Neuroscience 76 1997 1159 1171 (Pubitemid 27016088)
35. A. Nambu Seven problems on the basal ganglia Curr. Opin. Neurobiol. 18 2008 595 604
36. S. Navailles, and P. De Deurwaerdère The constitutive activity of 5-HT2C receptors as an additional modality of interaction of the serotonergic system in motor control G. Di Giovanni, V. Di Matteo, E. Esposito, The Pathophysiology of Central 5-HT2C Receptors 2011 Humana Press, Springer In: Neve, K. (Ed.), The Receptors series
37. Navailles, S.; Lagière, M.; Roumegous, A.; Polito, M.; Ben Boujema, M.; Cador, M.; Dunlop, J.; Chesselet, M.F.; Millan, M.J.; De Deurwaerdère, P. Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinsons disease. Int. J. Neuropsychopharmacol.; http://dx.doi.org/10.1017/S1461145712000417, in press.
38. S. Navailles, D. Moison, D. Ryczko, and U. Spampinato Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors J. Neurochem. 99 2006 1311 1319 (Pubitemid 44655294)
39. C.M. Niswender, S.C. Copeland, K. Herrick-Davis, R.B. Emeson, and E. Sanders-Bush RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity J. Biol. Chem. 274 1999 9472 9478
40. 2A receptor affinity J. Med. Chem. 38 1995 28 33
41. G. Paxinos, and C. Watson The rat brain in stereotaxic coordinates 2nd ed. 1986 Academic Press Australia
42. L. Rauser, J.E. Savage, H.Y. Meltzer, and B.L. Roth Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor J. Pharmacol. Exp. Ther. 299 2001 83 89 (Pubitemid 32905121)
43. E.S. Robinson, J.W. Dalley, D.E. Theobald, J.C. Glennon, M.A. Pezze, E.R. Murphy, and T.W. Robbins Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task Neuropsychopharmacology 33 2008 2398 2406
44. L.E. Rueter, L.H. Tecott, and P. Blier In vivo electrophysiological examination of 5-HT2 responses in 5-HT2C receptor mutant mice. Naunyn Schmiedebergs Arch. Pharmacol. 361 2000 484 491 (Pubitemid 30262596)
45. L.C. Scarlota, J.A. Harvey, and V.J. Aloyo The role of serotonin-2 (5-HT2) and dopamine receptors in the behavioral actions of the 5-HT2A/2C agonist, DOI, and putative 5-HT2C inverse agonist, SR46349B Psychopharmacology (Berl) 213 2011 393 401
46. V. Sgambato, V. Abo, M. Rogard, M.J. Besson, and J.M. Denaiu Effect of electrical stimulation of the cerebral cortex on the expression of the Fos protein in the basal ganglia Neuroscience 81 1997 93 112 (Pubitemid 27373631)
47. L.H. Tecott, L.M. Sun, S.F. Akana, A.M. Strack, D.H. Lowenstein, M.F. Dallman, and D. Julius Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors Nature 374 1995 542 546
48. W. Wan, D.J. Ennulat, and B.M. Cohen Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain Brain Res. 688 1995 95 104
49. C.A. Winstanley, D.E. Theobald, J.W. Dalley, J.C. Glennon, and T.W. Robbins 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion Psychopharmacology (Berl) 176 2004 376 385 (Pubitemid 40012745)
50. M.D. Wood, C. Reavill, B. Trail, A. Wilson, T. Stean, G.A. Kennett, S. Lightowler, T.P. Blackburn, D. Thomas, T.L. Gager, G. Riley, V. Holland, S.M. Bromidge, I.T. Forbes, and D.N Middlemiss SB-243213: a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety Neuropharmacology 41 2001 186 199 (Pubitemid 32728090)